Cruzado-Sánchez D, Salas-Diaz M, Tellez W A, Alvarez-Matos S E, Serpa-Frías S
Servicio de Oftalmología Oncológica, Departamento de Cabeza y Cuello, Instituto Nacional de Enfermedades Neoplásicas (INEN), Perú.
Universidad Nacional Federico Villarreal, Perú.
Arch Soc Esp Oftalmol. 2017 Nov;92(11):539-542. doi: 10.1016/j.oftal.2017.03.006. Epub 2017 May 15.
A 35 year-old male patient with a history of HIV infection characterized by progressive tumour growth in bulbar conjunctiva of the left eye, corresponding to conjunctival squamous cell carcinoma that responded to treatment with interferon alpha-2a.
Interferon alpha-2b has been used at conjunctival level as a topical immunomodulator treatment, with complete remission of epithelial neoplasms being observed. However, there have not been any previous publications on the use of interferon alpha-2a, which differs from interferon alpha-2b in a single amino acid, for the treatment of conjunctival squamous cell carcinoma.
一名35岁男性患者，有HIV感染史，其特征为左眼球结膜肿瘤进行性生长，诊断为结膜鳞状细胞癌，对α-2a干扰素治疗有反应。
α-2b干扰素已被用作结膜局部免疫调节剂治疗，观察到上皮肿瘤完全缓解。然而，此前尚无关于使用α-2a干扰素治疗结膜鳞状细胞癌的报道，α-2a干扰素与α-2b干扰素仅在一个氨基酸上不同。
